FY2025 EPS Estimates for Krystal Biotech Lowered by Analyst

Krystal Biotech, Inc. (NASDAQ:KRYS) – Equities researchers at Chardan Capital reduced their FY2025 earnings per share estimates for shares of Krystal Biotech in a note issued to investors on Tuesday, November 5th. Chardan Capital analyst Y. Livshits now expects that the company will post earnings per share of $5.78 for the year, down from their previous forecast of $8.69. Chardan Capital has a “Buy” rating and a $208.00 price target on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $2.96 per share.

Several other analysts have also recently issued reports on KRYS. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Stifel Nicolaus upped their target price on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. HC Wainwright reaffirmed a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research note on Tuesday. Evercore ISI upped their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Finally, William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $197.00.

Krystal Biotech Trading Up 7.6 %

KRYS stock opened at $199.61 on Friday. The stock has a market capitalization of $5.74 billion, a price-to-earnings ratio of 112.77 and a beta of 0.82. The firm’s 50-day moving average price is $181.29 and its two-hundred day moving average price is $180.58. Krystal Biotech has a 12-month low of $93.95 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.84 by $0.07. The company had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm’s revenue for the quarter was up 879.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.67) earnings per share.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 14.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently modified their holdings of the stock. Jamison Private Wealth Management Inc. purchased a new stake in Krystal Biotech during the 2nd quarter valued at about $28,000. GAMMA Investing LLC increased its position in Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after buying an additional 93 shares in the last quarter. Key Financial Inc bought a new position in shares of Krystal Biotech in the second quarter worth about $28,000. Blue Trust Inc. lifted its position in shares of Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after buying an additional 163 shares in the last quarter. Finally, Values First Advisors Inc. bought a new position in shares of Krystal Biotech during the 3rd quarter valued at approximately $53,000. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).